Yükleniyor... / Loading...
This study evaluated the safety of the drug VX-152 in combination with TEZ/IVA and IVA, compared with placebo, in adults with cystic fibrosis. It included patients with an eligible CFTR genotype (homozygous for F508del or heterozygous for F508del and a minimal function mutation). It was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Willing and able to comply with scheduled visits, treatment pan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. * Body weight ≥35 kg. * Sweat chloride value ≥ 60 mmol/L from test results obtained during screening. * Subjects must have an eligible CFTR genotype: * Cohorts 1A, 1B, 1C: Heterozygous for F508del and a minimal function mutation known or predicted not to respond to TEZ and/or IVA. * Cohorts 2A, 2B: Homozygous for F508del. * Subjects must have an FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height at the Screening Visit. * Stable CF disease as judged by the investigator. * Willing to remain on a stable CF medication regimen through the planned end of treatment or if applicable the Safety Follow-up Visit. Exclusion Criteria: * History of any comorbidity that in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject. * History of cirrhosis with portal hypertension. * Risk factors for Torsade de Pointes. * History of hemolysis. * Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening. * Clinically significant abnormal laboratory values at screening. * An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before the first dose of study drug. * Lung infection with organisms associated with a more rapid decline in pulmonary status. * An acute illness not related to CF within 14 days before the first dose of study drug. * A standard digital ECG demonstrating QTc \>450 msec at screening. * History of solid organ or hematological transplantation. * History or evidence of cataract or lens opacity determined to be clinically significant by the ophthalmologist or optometrist, based on the ophthalmologic examination during the Screening Period. * History of alcohol or drug abuse in the past year, including but not limited to, cannabis, cocaine, and opiates, as deemed by the investigator. * Ongoing or prior participation in an investigational drug study with certain exceptions. * Use of commercially available CFTR modulator within 14 days before screening (applies only to Cohorts 1A, 1B, and 1C). * Pregnant or nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1.